Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MicroRNA-200b-5p functions as a suppressor via directly targeting FGF4 in chronic HBV virological breakthrough

ABSTRACT: MiR-200b-5p as a suppressor by targeting FGF4

PROVIDER: PRJEB35678 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

MicroRNA-200b-5p functions as a suppressor via directly targeting FGF4 in chronic HBV virological breakthrough

Project description:MiR-200b-5p as a suppressor by targeting FGF4

| PRJEB35679 | ENA

6 h FGF4 stimulation in Fgf4-mutant and Fgf4 Med12 double mutant mESCs [bulkRNA-seq]

Project description:6 h FGF4 stimulation in Fgf4-mutant and Fgf4 Med12 double mutant mESCs [bulkRNA-seq]

| PRJNA1066348 | ENA

FGF4 stimulation increases variability in mESCs [scRNA-seq]

Project description:FGF4 is essential for Epiblast and Primitive Endoderm formation in the mouse embryo and promotes differentiation of mouse embryonic stem cells. However, different FGF-concentrations regulate gene expression quantitatively remained an open question. We used single-cell RNA sequencing to quantify transcriptional variability and dynamics upon FGF4 stimulation of Fgf4-mutant mESCs.

2025-02-26 | GSE256059 | GEO

6 h FGF4 stimulation of Fgf4-mutant mESCs [bulkRNA-seq]

Project description:6 h FGF4 stimulation of Fgf4-mutant mESCs [bulkRNA-seq]

| PRJNA1066347 | ENA

FGF4 is a target of EWS-OCT-4 in Embryonic stem cell

Project description:FGF4 has key role in self-renewal and differentiation of Embryonic stem cell, and Fgf4 is activated by direct binding of ESW-OCT-4 through its enhancer

2018-08-08 | GSE118212 | GEO

The FGF4-dependent phosphoproteome in mouse embryonic stem cells

Project description:Protein kinase signalling is a major mechanism by which embryonic stem cell pluripotency and differentiation is controlled. However, the pathways and components that regulate embryonic stem cell identity have not been systematically defined. Here, we employ FGF4 signalling as a model system to investigate phosphoproteome dynamics in differentiating mouse embryonic stem cells. We report identification and quantitation of more than 10,000 phosphopeptides, of which hundreds of phosphophoylation sites are regulated more than 2-fold by acute FGF4 stimulation. We hypothesise that phosphorylation sites in this dataset are relevant for regulating the transition of mouse embryonic stem cells from pluripotency towards lineage specific differentiation.

2020-02-24 | PXD012069 | Pride

miR-200b is associated with cisplatin sensitivity in bladder cancer cells

Project description:We aimed to clarify the role of miR-200b in cisplatin (CDDP) sensitivity in bladder cancer (BCa). CDDP resistant T24 cells (T24RC) were transfected with a miR mimic negative control (NC) or a miR-200b mimic, after which cells were treated with or without CDDP. We found that ectopic miR-200b expression re-sensitized the T24RC cells to CDDP. Gene expression microarray analysis revealed that the combination of miR-200b and CDDP affected genes involved in CDDP sensitivity and cytotoxicity.

2018-05-31 | GSE103250 | GEO

RNA-seq analysis of bta-miR-200b overexpression in bovine endometrial epithelial cells

Project description:To investigate the gene bta-miR-200b induced cell apoptosis, we used the BEND that transinfected with bta-miR-200b and mimic NC

2022-08-27 | GSE211959 | GEO

On-treatment HBV DNA dynamics predict virological breakthrough in entecavir-treated HBeAg-positive chronic hepatitis B.

Project description:Background & aimsVirological breakthrough (VBT) could be a manifestation of chronic hepatitis B (CHB) in patients treated with long-term nucleot(s)ide analogues. We aimed to determine the association of on-treatment serum hepatitis B virus (HBV) DNA with VBT in HBeAg-positive CHB patients receiving entecavir (ETV) treatment.MethodsA retrospective cohort study, including 162 consecutive patients (95 men and 67 women; mean age, 43.1±13.4 years) with HBeAg-positive CHB treated with ETV for at least 48 weeks between August 2008 and May 2015, was conducted. Univariate and multivariate cox regression analysis were used to identify associations with VBT and clinical factors, including HBV DNA and HBeAg serum status.ResultsAmong the 162 ETV-treated HBeAg-positive CHB patients, eighteen patients (11.1%) experienced VBT (VBT group), whereas the other 144 patients were without VBT (non-VBT group). The cumulative rate of HBV DNA < 100 IU/mL in the VBT group and the non-VBT group at week 48 were 44.44% and 70.14%, and at week 96 were 58.33% and 92.56%, respectively (p = 0.015). The cumulative rate of HBeAg seroclearance in the VBT group and non-VBT group at week 48 and week 96 were statistically significant (p = 0.014). Multivariate analysis disclosed that failure to achieve HBeAg seroclearance were the factors significantly associated with VBT.ConclusionsOur results demonstrated that on-treatment HBV DNA could probably predict VBT in ETV-treated HBeAg-positive chronic hepatitis B patients. Failure to achieve HBeAg seroclearance was associated with VBT in ETV-treated HBeAg-positive CHB patients. HBV DNA >100IU/mL at 48 weeks is potentially a predictor for VBT.

| S-EPMC5369759 | biostudies-literature

Target proteins of miR-200b in AIPC by label free proteomics

Project description:For androgen-independent prostate cancer (AIPC), the current treatment is limited and the prognosis is poor. We previously found miR-200b could inhibit androgen independent proliferation ability of prostate cancer cells, but the mechanism is unclear. MiRNAs plays their role by blocking translation through base-pairing with complementary mRNA and by promoting degradation of target mRNA. Unraveling the miRNA translational silencing network remains a challenge in part because a single miRNA can inhibit multiple mRNA targets and because a single mRNA can be regulated by several distinct miRNAs that act cooperatively. However, proteomics methods provide us useful tools to unravel the target genes network. This study identified the target genes of miR-200b in AIPC. It helps us to understand the mechanism of AIPC and applies several new candidate targets of AIPC treatment.

2020-08-05 | PXD006350 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data